George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Pete,
We reached 5.30 in the middle of covid quite easily, we are now in control of the disease to some extent.
This can easily recover to 5.30 plus in the forthcoming weeks.
remember we were trading at £10 level before covid
Looks like they are heading in the right direction.
Financially stable with a great business model, low reduced overheads and plenty of possible clients in the pipeline.
Very promising.
Thought you was another dabbler i know of !!!!
Horace,
knock it on the head..... i'm just reminiscing of the times when i used to be able to visit the pub, ice cold pint in hand, leaning against the bar..... aggghhhhhhhh
Might see ya in there downoutbutnot.... if share conversation crops up at the bar lol :-)
No too far from Narborough.
I like old Aylestone, been in the Black horse a few times for a quick pint
that makes three of us,,
Anywhere near Narborough ?
Dabbler......
Countesthorpe, Leicester ??
Oxford University-AstraZeneca coronavirus vaccine
AstraZeneca, which has already begun phase III human trials of its AZD1222 (formerly known as ChAdOx1 nCoV-19) vaccine candidate, signed its tenth supply-and-manufacturing deal. Brazil announced on Saturday it had signed a $127 million agreement to start producing locally the Oxford-AstraZeneca vaccine.
Elcio Franco, Brazil’s No 2 public health official, said in a press conference that the country would initially produce 30 million doses of the vaccine — half by December and half by January of next year, Reuters reported.
Vaccine is not far away
Development of New Vaccines
The general stages of the development cycle of a vaccine are:
Exploratory stage
Pre-clinical stage
Clinical development
Regulatory review and approval
Manufacturing
Quality control
Clinical development is a three-phase process. During Phase I, small groups of people receive the trial vaccine. In Phase II, the clinical study is expanded and vaccine is given to people who have characteristics (such as age and physical health) similar to those for whom the new vaccine is intended. In Phase III, the vaccine is given to thousands of people and tested for efficacy and safety.
Many vaccines undergo Phase IV formal, ongoing studies after the vaccine is approved and licensed.